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Department 01 Ethics 
Abstract: It has been one of the frames for discussion on the ethical issues of gene therapy 
to distinguish gene transfer techniques that aim at therapy from those that aim at the 
enhancement of normal human traits. However， the recent improvement in techniques of 
gene therapy has raised conditions so that the treatment/enhancement distinction itself 
must be reexamined on new grounds. For example， there are a multidrug resistance 
(MDR) protocol for patients with advanced cancer and gene therapy trials for cancer 
involving insertion of the tumor necrosis factor (TNF) gene into T -lymphocytes. These 
protocols， in contrast with a typical substitution-type gene therapy， try to increase a 
natural trait of some of our cells. Such gene therapy involves the enhancement of the body' 
s health maintenance capacities. If the gene transfer techniques are thus used for the 
enhancement of our health maintenance capacities， then the boundary between treatment 
and enhancement could not be applied to confining the limits of the proper medical use of 
gene transfer techniques. How can one stil draw an ethicalline between therapy and mere 
enhancement? The question of such a boundary compels us to reconsider an difficult 
problem about the concept of“disease" . 
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伝子治療、(3 )増進的遺伝子工学、(4 )優生学的遺伝子工学。ここでは)と(4 )の分類
は、先の(タイプ3)と(タイプ4)の分け方とは若干異なる。先のタイプでは、治療ではな
くて、ヒト形質の能力増進を目的とする遺伝子介入が、体細胞への遺伝子挿入であるか、或い









































アンダーソンは、遺伝子治療の代表的推進者の 1人である o そうした立場から、遺伝子治療、
ヒト遺伝子導入についての倫理的議論の枠組みとして、 2つの対立軸を設定する o その対立軸
は、遺伝子治療の倫理問題に関して、どういうスタンスをとるかにかかわらず、彼に限らず多
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